January 21, 2026
This article discusses APTN-101, the Brain Bispecific T-cell Engager behind the Khasraw lab-led BRiTE trial. In advanced preclinical testing, APTN-101 demonstrated targeted anti-tumor activity and a favorable safety profile. APTN-101 is now being translated into a Phase 1 first-in-human trial at Duke’s Preston Robert Tisch Brain Tumor Center.
Read the full article here.